Correlation Between Acumen Pharmaceuticals and Eledon Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Acumen Pharmaceuticals and Eledon Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acumen Pharmaceuticals and Eledon Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Acumen Pharmaceuticals and Eledon Pharmaceuticals, you can compare the effects of market volatilities on Acumen Pharmaceuticals and Eledon Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acumen Pharmaceuticals with a short position of Eledon Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acumen Pharmaceuticals and Eledon Pharmaceuticals.

Diversification Opportunities for Acumen Pharmaceuticals and Eledon Pharmaceuticals

0.07
  Correlation Coefficient

Significant diversification

The 3 months correlation between Acumen and Eledon is 0.07. Overlapping area represents the amount of risk that can be diversified away by holding Acumen Pharmaceuticals and Eledon Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eledon Pharmaceuticals and Acumen Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acumen Pharmaceuticals are associated (or correlated) with Eledon Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eledon Pharmaceuticals has no effect on the direction of Acumen Pharmaceuticals i.e., Acumen Pharmaceuticals and Eledon Pharmaceuticals go up and down completely randomly.

Pair Corralation between Acumen Pharmaceuticals and Eledon Pharmaceuticals

Given the investment horizon of 90 days Acumen Pharmaceuticals is expected to under-perform the Eledon Pharmaceuticals. In addition to that, Acumen Pharmaceuticals is 1.2 times more volatile than Eledon Pharmaceuticals. It trades about -0.17 of its total potential returns per unit of risk. Eledon Pharmaceuticals is currently generating about 0.22 per unit of volatility. If you would invest  402.00  in Eledon Pharmaceuticals on November 18, 2024 and sell it today you would earn a total of  51.00  from holding Eledon Pharmaceuticals or generate 12.69% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Acumen Pharmaceuticals  vs.  Eledon Pharmaceuticals

 Performance 
       Timeline  
Acumen Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Acumen Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Eledon Pharmaceuticals 

Risk-Adjusted Performance

Modest

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Eledon Pharmaceuticals are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very weak fundamental indicators, Eledon Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

Acumen Pharmaceuticals and Eledon Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Acumen Pharmaceuticals and Eledon Pharmaceuticals

The main advantage of trading using opposite Acumen Pharmaceuticals and Eledon Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acumen Pharmaceuticals position performs unexpectedly, Eledon Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eledon Pharmaceuticals will offset losses from the drop in Eledon Pharmaceuticals' long position.
The idea behind Acumen Pharmaceuticals and Eledon Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Complementary Tools

Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance